Giselle Mosnaim, MD, MS

Panelists discuss how chronic spontaneous urticaria (CSU) treatment targets multiple pathways through antihistamines, anti-IgE therapy, and BTK inhibitors, with BTK emerging as a key target.

Panelists discuss how chronic spontaneous urticaria develops through 2 distinct pathways: autoallergic CSU involving IgE-mediated mast cell activation (type I hypersensitivity) and autoimmune CSU where IgG autoantibodies target FcεRI receptors or IgE itself (type IIb hypersensitivity), both ultimately leading to mast cell degranulation and wheal formation.